The primary objectives of this study are to: (i) derive quantitative measures of behaviour on the basis of smartphone monitoring in a healthy cohort and a cross-diagnostic cohort of patients with mental disorders (e.g. depression, anxiety and…
ID
Source
Brief title
Condition
- Anxiety disorders and symptoms
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
- Behavioural phenotypes derived from fitting a machine learning models (e.g.
hidden Markov models) to timeseries of smartphone sensor data provided by the
BeHapp platform.
- Parameters from multi-modal neuroimaging data from healthy individuals and
individuals with mental disorders (e.g. measures of cortical thickness derived
from structural MRI, functional connection strength derived from resting state
fMRI).
- cross-diagnostic symptom scores across different functional domains (latent
factor scores derived from a factor analysis).
Secondary outcome
- Subject-level deviation maps derived from normative models of
neuroimaging-based measures and behavioural phenotypes derived from smartphone
measures (e.g. subject level Z-statistic images)
- Measures of subject-level overlap across these measures
Background summary
In many areas of medicine -for example oncology- quantitative markers of
biology have transformed diagnosis and treatment allocation, allowing for
targeted and personalized interventions in the spirit of *precision medicine*
ultimately leading to better outcomes for patients and a better understanding
of disease entities. This is not the case in psychiatry, where disorders are
still diagnosed on the basis of symptoms and biomarkers to assist treatment
allocation remain to be developed. Finding markers to predict and stratify
mental disorders is a formidable goal that requires understanding their impact
across multiple levels from neurobiology to behaviour. Advances in neuroimaging
provide unprecedented ability to measure neurobiology non-invasively across
increasingly large cohorts. Simultaneously, the near ubiquity of smartphone
technology in modern life makes it possible to measure behaviour
quantitatively, unobtrusively and in real-world situations using digital
phenotyping. However, the potential of these techniques for improving clinical
decision-making is not being realized due to a lack of analysis tools to chart
variation across individuals, to integrate complimentary information from
different data modalities and to predict trajectories of functioning at the
level of the individual.
Study objective
The primary objectives of this study are to: (i) derive quantitative measures
of behaviour on the basis of smartphone monitoring in a healthy cohort and a
cross-diagnostic cohort of patients with mental disorders (e.g. depression,
anxiety and substance use disorders); (ii) establish the validity of these as
measures of mental state by performing quantitative comparisons of individuals
with mood disorders against healthy controls (i.e. in a case-control sense and
via continuous associations with symptom levels) and using these measures to
predict subjective mood scores acquired on a moment-to-moment basis using
ecological momentary assessment; (iii) combine these measures with multi-modal
neuroimaging data to predict measures of mental health across the spectrum of
functioning. For this we will use normative models (*brain growth charts*) to
bind different samples into a common reference space. Throughout this project
behaviour will be conceptualised and quantified in terms of functional domains
(e.g. negative valence, arousal/inhibition) approximately corresponding to
those outlined in the Research Domain Criteria framework.
Study design
Observational cross-sectional study
Study burden and risks
Burden: All subjects will visit the study centre for an intake visit, where
they will install the necessary software on their smartphone and be instructed
on the use of the ecological momentary assessments (approximately 1 hour).
Participants in the clinical group will also visit the study centre a second
time, during which a standardized neuroimaging protocol will be acquired (total
1.5 hours). The use of patients in this study is necessary because the goal is
to develop quantitative and ecological measures of behaviour that can be used
to predict functioning in mental disorders.
Risks: Minimal risk
Benefits: While there will be no direct benefit to the participants themselves,
the study may contribute knowledge that may be helpful in the future for
patients with the same mental disorders
Kapittelweg 29
Nijmegen 6525EN
NL
Kapittelweg 29
Nijmegen 6525EN
NL
Listed location countries
Age
Inclusion criteria
Healthy cohort:
- Volunteer aged 16-80, who has participated in prior studies at the Donders
Centre for Cognitive Neuroimaging and for whom neuroimaging data are available
(see protocol for details)
- Has provided consent to be re-contacted for future research
- Possesses and uses an Android smartphone (required for the BeHapp software)
Patient cohort:
- Volunteer who has participated in the MIND-Set 2 study. This means the
subject is:
-- Adult (age >=16) in- and outpatient at the Department of Psychiatry of the
Radboudumc
-- Referred for a diagnostic and/or treatment question relating to either
stress-related (mood, anxiety), neurodevelopmental (ASD, ADHD, personality)
and/or impulse-regulation disorders.
These criteria are assessed by the clinician during the intake interview, and
will be confirmed through detailed diagnostic interviews.
- Has provided consent to be contacted about participation in other studies.
- Possesses and uses an Android smartphone (required for the BeHapp software)
Exclusion criteria
- Cannot speak, read and/or understand Dutch (VMBO level) and English (working
profiiency)
- Prior history of significant neurological illnesses
- Pregnancy
- Standard contra-indication for MRI:
-- unsafe metal or devices in the body (Cardiac Pacemaker, cochlear implant,
aneurism clip)
-- previous brain surgery
-- moderate to severe claustrophobia
Additional exclusion criteria for healthy controls:
- Current disease that affects the brain
- Prior history of significant psychiatric illness
- Neurological disorders of the central nervous system
- Fifteen or more units of alcohol per week
- Recreational drug use of once or more per week
- Benzodiazepine use of once or more per week
- Malignancies
- Rare, chronic somatic disorders
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL82527.091.22 |